

**Prof. Hüseyin Abalı**

Call: 90.322.4554444

ACIBADEM UNIVERSITY

Cell phone: +905326710541

MEDICAL FACULTY

Fax: +90.322.4554466

DEPARTMENT OF INTERNAL

E-mail: dr.huseyinabali@yahoo.com

MEDICINE MEDICAL ONCOLOGY

DIVISION

*Hüseyin Abalı*

<b>Personal Information</b>	<ul style="list-style-type: none"><li>• Marital Status: Married</li><li>• Date of Birth: March 01, 1970</li><li>• Place of Birth: Mersin-Turkey</li></ul>
<b>Education</b>	<ul style="list-style-type: none"><li>• 1985-1987: Arslanköy High School (Mersin)</li><li>• 1987-1988: Mersin Tevfik Gür High School,</li><li>• 1988-1995: Medical Education at Hacettepe University Medical Faculty (English group),</li><li>• 1995-2000: Residency in internal medicine at Hacettepe University Medical Faculty Department of Internal Medicine,</li><li>• 2000-2003: Fellowship in medical oncology at Hacettepe University Institute of Oncology,</li><li>• 2006: Associate Professor</li><li>• 2011: Professor</li></ul>
<b>Work Experience</b>	<ul style="list-style-type: none"><li>• 2003-2006: Specialist in medical oncology at Ministry of Health Ankara Numune research and Teaching Hospital Medical Oncology Clinic</li><li>• 2006-2008: Associate Professor at Mersin University Medical Faculty Department of Internal Medicine, Division of Medical Oncology</li><li>• 2008-2011: Associate Professor at Başkent University Medical Faculty Department of Internal Medicine, Division of Medical Oncology</li><li>• 2011-2014: Professor at Başkent University Medical Faculty Department of Internal Medicine, Division of Medical Oncology</li><li>• 2014-Current: Department of Medical Oncology at Acibadem Adana Hospital</li></ul>

<p><i>Awards and Achievements</i></p>	<ul style="list-style-type: none"> <li>• 1996: ECFMG (<i>Educational Commission for Foreign Medical Graduates</i>) Certificate</li> <li>• 1999: Prof. Dr. M. Şeref Zileli Resident of the Year Award</li> <li>• 1998-1999: Selected Chief Resident at Department of Internal Medicine</li> <li>• 2003: ICH Good Clinical Practice Training Course For Clinical Investigators</li> <li>• 2003: ASCO/AACR/EORTC Workshop FECS – AACR – ASCO Workshop “Methods in Clinical Cancer Research” Park Hotel Waldhaus, Flims (Switzerland) - 21 - 27 June 2003</li> <li>• 2005: Roche Pharmaceuticals Research Award, XVI.<sup>th</sup> National Cancer Congress, April 20-24, 2005; Antalya</li> <li>• 2007: Best Clinical Research Project Award, 2nd Turkish Oncology Group Workshop, Ankara Bilkent Hotel</li> <li>• Visiting Physician to Brigham and Women Hospital, Dana Farber Cancer Center and Massachusetts General Hospitals, October 11<sup>th</sup>, 2009-31<sup>st</sup>, October 2009</li> </ul>
<p><i>Memberships</i></p>	<ul style="list-style-type: none"> <li>• Flims Alumni Club (“Federation of European Cancer Societies” affiliate), “General Secretary”</li> <li>• The European Group For Blood and Bone Marrow Transplantation “EBMT”</li> <li>• European Society of Medical Oncology</li> <li>• American Society of Clinical Oncology</li> <li>• Multinational Association for Supportive Care in Cancer</li> <li>• Member of Steering Committee of Turkish Society of Medical Oncology (2012-2014, 2014-)</li> <li>• Associate editor of Journal of Oncological Sciences (Official Journal of TSSMO)</li> </ul>
<p><i>Other</i></p>	<ul style="list-style-type: none"> <li>• Associate Editor: Journal of Oncological Sciences (2016)</li> </ul>

<p><b>Selected Publications</b></p>	<ul style="list-style-type: none"> <li>• <i>Editor in Chief: Journal of Oncological Sciences (2017-Present)</i></li> <li>• Ozdemir N, Abali H, Vural M, Yalcin S, Okşuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOFAX study. <i>Cancer Chemother Pharmacol.</i> 2014 Dec;74(6):1139-47. doi: 10.1007/s00280-014-2586-6. Epub 2014 Sep 19. Erratum in: <i>Cancer Chemother Pharmacol.</i> 2015 Jul;76(1):217. PubMed PMID: 25234436.</li> <li>• Sezer A, Sümbül AT, <b>Abali H</b>, Mertsoylu H, Ozyulgan O. Malignant pleural mesothelioma: a single-center experience in Turkey. <i>Med Sci Monit.</i> 2014 May 20;20:825-32. doi: 10.12659/MSM.890020. PubMed PMID: 24842043; PubMed Central PMCID: PMC4038637.</li> <li>• <b>Abali H</b>, Celik I. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. <i>Cancer Invest.</i> 2007;25:135-9</li> <li>• Okşuzoglu B, <b>Abali H</b>, Bakır M, Yıldırım N, Zengin N. Disclosure of cancer diagnosis patients and their relatives in Turkey: views of accompanying persons and influential factors in reaching those views. <i>Tumori.</i> 2006;92:62-6.</li> <li>• Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, <b>Abali H</b>, Celik I, Bozkurt A. Association of the ABCB1 3435C&gt;T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. <i>Clin Pharmacol Ther.</i> 2005;78:619-26.</li> <li>• <b>Abali H</b>, Oyan B, Koc Y, Kars A, Barista I, Uner A, Turker A, Demirkazik F, Tekin F, Tekuzman G, Kansu E. IFVP salvage regimen induces high response rates in patients with relapsed lymphoma prior to autologous stem cell transplantation. <i>Am J Clin Oncol</i> 2005;28:264-269</li> <li>• <b>Abali H</b>, Oyan B, Guler N. Alprazolam significantly improves efficacy of granisetron in prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer. <i>Chemotherapy</i> 2005;51:280-285</li> <li>• Erman M, Baltali E, Karaoglu A, <b>Abali H</b>, Engin H, Ozisik Y, Guler N, Altundag K, Tekuzman G. A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer. <i>Cancer Investigation</i> 2005;23:211-217</li> <li>• Erman M, <b>Abali H</b>, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I. Tamoxifen induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? <i>Ann Oncol</i> 2004;15:1622-6.</li> <li>• Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E. Who Benefits Most From Adjuvant Interferon Treatment for Melanoma? <i>Am J Ther.</i> 2013 Oct 30. [Epub ahead of print] doi: 10.1097/MJT.0b013e31829e883d</li> <li>• Beköz H, Karadurmus N, Paydas S, Türker A, Toptas T, Firatlı Tuğlular T, Sönmez M, Gülbas Z, Tekgündüz E, Kaya AH, Özbalak M, Tastemir N, Kaynar L, Yıldırım R, Karadogan I, Arat M, Pepedil Tanrikuşlu F, Özkoçaman V, <b>Abali H</b>, Turgut M, Kurt Yüksel M, Özcan M, Dogu MH, Kabukçu Hacıoglu S, Barista I, Demirkaya M, Köseoğlu FD, Toprak SK, Yılmaz M, Demirkürekcü HC, Demirkol O, Ferhanoglu B. Nivolumab for</li> </ul>
---	--

	<p><i>relapsed or refractory Hodgkin lymphoma: real-life experience_ Ann Oncol.</i> <i>2017;28(10):2496-2502.</i></p>
--	---